{"description":"The study was closed prematurely due to poor accrual and substantial loss to follow-up of patients.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":6,"description":"Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.\n\nPembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.","id":"EG000","otherNumAffected":2,"otherNumAtRisk":6,"seriousNumAffected":2,"seriousNumAtRisk":6,"title":"Pembrolizumab 200 mg"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Hyponatremia"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Hypoalbuminemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6,"numEvents":1}],"term":"Constipation"}],"timeFrame":"From baseline through one year after the end of the study, up to 2 years."}